Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) stock is presently standing at about $17.03 and lots of equity research firms seem to have a target price set on the stock. The median one-year price target of 12 analysts covering the company is $17.25, which suggests the stock could still rise over 1 percent. The highest analyst price target is $21.00, which implies a rally of 77 percent. And a quick view of analyst notes show that 3 are rating the stock a buy while 2 rate IRWD a strong buy. There are 6 equity research firms advocating a Hold and 0 consider it Sell.
Goldman analysts provided their view on Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) recently. The rating firm issued a Neutral rating to this company in a research note released on Mar 21, 2016. BofA/Merrill analysts disclosed their opinion on Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) recently. The rating firm gave a Buy rating to this stock in a research note published on Apr 27, 2015. According to a research note disclosed on Jul 24, 2013, analysts at Cantor Fitzgerald have upped their rating on these shares from Sell to Hold.
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Transactions Roundup
Several insiders were part of recent insider activity for the stock. Its Director OLANOFF LAWRENCE S sold 3,200 company shares for 55010, in a transaction on 2017-03-03. Following the transaction, the Director is left with a stake of 22,905 shares, currently valued at $390072. Meanwhile, Chief Accounting Officer Consylman Gina sold 2,962 shares worth $48960, through a transaction dated 2017-02-24. Following the completion of the transaction, the insider is left with a stake of 53,072 shares, amounting $903816.16. IRWD Chief Scientific Officer Currie Mark G also sold 1,800 shares, at a stock price of $16.94. This transaction occurred on 2017-02-22 totals $30490. After this transaction, the insider’s stake stands at 775,000 shares, with a market value of $13198250.
Executives hold 5.38 percent of the stock. Mr. Edward P. Owens is one of the biggest insider owners in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD), according to U.S. Securities and Exchange Commission (SEC) filings. The insider owns 167,680 shares which have current market value of around $2855590.4.Halley E. Gilbert is another major inside shareholder in the company. The insider owns 100,807 shares as of less than 0.1%, currently worth $1716743.21. Dr. Christopher T. Walsh,PhD is ranked as third insider holder of the stock. This insider holds 71,357 shares with a market value around $1215209.71 as of recent close.
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Earnings Outlook
In Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD)’s latest quarter, EPS moved to $-0.09 from $-0.23 in preceding quarter and revenues reached at $87.46M compared to $66.11M. Analysts had expected Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) to post net income of about $-0.24 per share on $76.93M in revenue. Looking ahead, analysts on average predict that earnings for the current quarter would come in in the range of $-0.27 to $-0.09. That is compared with the $-0.09 in EPS it reported during the same period a year ago.